| For: | Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer: Is there enough evidence to call second-line therapy standard? World J Gastroenterol 2012; 18(44): 6376-6378 [PMID: 23197882 DOI: 10.3748/wjg.v18.i44.6376] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i44/6376.htm |
| Number | Citing Articles |
| 1 |
Gebra Cuyun Carter, Denise T. King, Lisa M. Hess, Stephen A. Mitchell, Kaisa-Leena Taipale, Urpo Kiiskinen, Narayan Rajan, Diego Novick, Astra M. Liepa. Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review. Journal of Medical Economics 2015; 18(11) doi: 10.3111/13696998.2015.1066380
|
| 2 |
Ya-Kun Jiang, Wei Li, Ying-Yang Qiu, Meng Yue. Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer. World Journal of Gastrointestinal Oncology 2024; 16(6): 2318-2334 doi: 10.4251/wjgo.v16.i6.2318
Abstract(667) |
Core Tip(723) |
Full Article(HTML)(2591)
|
Full Article (PDF)-10027K(230)
|
Full Article with Cover (PDF)-10337K(243)
|
Full Article (XML)-321K(136)
|
Audio-441K(14)
|
Peer-Review Report-231K(151)
|
Answering Reviewers-70K(137)
|
Supplementary Material-8723K(151)
|
Times Cited (5)
|
Total Visits (3748)
|
Open
|
| 3 |
Carles Pericay, Fernando Rivera, Carlos Gomez‐Martin, Inmaculada Nuñez, Alejo Cassinello, Esteban Rodrigo Imedio. Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Medicine 2016; 5(12) doi: 10.1002/cam4.941
|
| 4 |
Xiao Yang, Kaiyuan Deng, Fengning Wang, Qiao Liu, Xinyao Du, Yujiao Yang, Zhihui Yang, Mengqi Yang, Liping Wang, Xin Wang, Shumin Lu, Linkun Wang, Yuang He, Xiang Zhao, Jiahui Zhang, Fei Xu, Jiazeng Xia. Identification of candidate hub genes and signatures in gastric adenocarcinoma: the role of <i>CDRT15P1</i> in tumor progression. Gastrointestinal Tumors 2026; 13(1) doi: 10.48130/git-0026-0011
|